Long-term experience with intranasal bevacizumab therapy

The Laryngoscope
Johan SteinegerSinan Dheyauldeen

Abstract

Long-term follow-up of intranasal bevacizumab therapy in hereditary hemorrhagic telangiectasia (HHT). Prospective, noncomparative study. Patients treated for HHT-associated epistaxis by intranasal submucosal bevacizumab injections between June 2011 and August 2013 were included and followed prospectively. The effectiveness of the treatment was evaluated by the epistaxis severity score (ESS); the epistaxis intensity, frequency, and the need of blood transfusion (IFT) score; and hemoglobin levels. Thirty-three patients were included. The total number of treatments with intranasal bevacizumab injection was 210. The mean number of treatments per patient was 6.2 ± 4.6 (range, 1-16), and the mean treatment and observation period was 38.8 ± 21.8 months (range, 2-66 months). Four patients showed no improvement after treatment. Eleven patients (33.3%) showed initial improvement in both ESS and IFT, but the treatment was discontinued before the end of the study because the effect became gradually shorter lasting despite repeated injections. Twelve patients (36.3%) continued to have a positive response to the treatment at the end of the study. No local adverse effects were observed, but one patient developed osteonecrosis in both knees du...Continue Reading

References

Sep 15, 1999·American Journal of Rhinology·V J Lund, D J Howard
Jan 18, 2005·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Giovanna PasculliCarlo Sabbà
May 17, 2006·Wiener klinische Wochenschrift·Haneen SadickKarl Hörmann
Apr 25, 2007·Chronobiology International·Haneen SadickMaliha Sadick
Dec 29, 2007·Current Opinion in Ophthalmology·Christopher M Andreoli, Joan W Miller
Feb 1, 2008·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Andrew MitchellLuc Delriviere
Apr 2, 2009·European Journal of Human Genetics : EJHG·Fatima S Govani, Claire L Shovlin
May 15, 2009·The New England Journal of Medicine·Prithviraj BoseGeorge B Selby
Jun 3, 2009·Current Vascular Pharmacology·Roberto ZarrabeitiaLuisa-Maria Botella
Dec 10, 2009·The Laryngoscope·Terence M DavidsonJulie L Wei
Jan 21, 2010·The Laryngoscope·Jeffrey B HoagChristian A Merlo
Aug 2, 2011·European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·C RohrmeierT S Kuehnel
Sep 16, 2011·American Journal of Otolaryngology·Brian T BrinkerhoffDavid M Poetker
Apr 2, 2013·American Journal of Otolaryngology·Osama A MarglaniOmar A Abu Suliman
May 16, 2013·British Journal of Haematology·Charles AldermanJonathan Cullis
Sep 7, 2016·JAMA : the Journal of the American Medical Association·Sophie Dupuis-GirodFrédéric Faure
Sep 7, 2016·JAMA : the Journal of the American Medical Association·Kevin J WhiteheadJames R Gossage

❮ Previous
Next ❯

Citations

Jul 10, 2019·The Laryngoscope·Johan SteinegerSinan Dheyauldeen
Sep 29, 2020·Laryngo- rhino- otologie·Caroline Theresa SeebauerKornelia Elisabeth Andorfer
Mar 5, 2021·European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·Cilgia DürM Caversaccio

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.